Secondary Malignant Neoplasm¶

A malignant lesion at a nonprimary anatomical site that is attributed to cancer originating elsewhere, preserving the primary cancer's identity while separately representing the site it has involved.

Version: v2 · 2026-09-06 · History
Domain-specific #: 2732
Origin domain: oncology
Subdomain: metastatic disease classification
Aliases: Secondary cancer, Secondary tumor

Core Idea¶

A secondary malignant neoplasm is malignant cancer at an anatomical site other than the site where that cancer originated, when the lesion at the involved site is attributed to spread from the primary cancer. The concept records two facts that must not be collapsed: where malignant tissue is now present and which cancer it remains. Thus breast cancer that has spread to the lung produces a secondary tumor in the lung, but the tumor remains breast cancer rather than becoming a primary lung cancer. The National Cancer Institute (NCI) uses secondary cancer and secondary tumor for this relationship and stresses that the cells at the secondary site are the same cancer type as those of the primary.^[1]^[2]

This entry deliberately corrects the frozen Wikipedia seed. That revision defined the term as a different cancer caused by earlier chemotherapy or radiotherapy. Authoritative oncology terminology assigns that situation to a second primary cancer, potentially treatment-related, not to a secondary malignant neoplasm in the metastatic-site sense. NCI explicitly distinguishes a new primary after earlier cancer or treatment from metastatic cancer, while the World Health Organization's ICD-10 guidance uses categories C77–C79 for neoplasms stated or inferred to be secondary to another site.^[3]^[4]^[5]

The candidate survives because it is more than a billing label and more specific than the process word metastasis. Metastasis names the spread of cancer cells and the biological sequence by which they invade, travel, lodge, and grow. Secondary malignant neoplasm classifies the resulting malignant involvement at a specified secondary site while retaining its primary lineage. That site–origin pairing is used in clinical documentation, staging, pathology, tumor registration, epidemiology, and coding. ICD codes operationalize the distinction, but neither create the clinicopathologic relation nor exhaust its meaning.^[6]^[7]

Structural Signature¶

the malignant lineage — a cancer defined by its originating tissue, histology, molecular evidence, or accepted clinicopathologic identity;
the primary site — the site where the malignant lineage arose, whether currently active, eradicated, or not yet identified;
the involved site — a different anatomical site in which malignant tissue is detected;
the secondary lesion or involvement — malignant cells growing at the involved site rather than merely passing through it;
the origin attribution — documentation or medical evidence that the lesion at the involved site derives from a malignancy arising elsewhere;
the identity-preservation rule — anatomical relocation does not rename the cancer after the secondary organ; metastatic breast cancer in lung remains breast cancer;
the two-coordinate description — cancer lineage or primary site and current secondary site are represented separately;
the classification boundary — the relation is not inferred from multiplicity, adjacency, chronology, or a patient's treatment history alone;
the uncertainty state — the primary may be unknown while evidence still establishes that the observed lesion is secondary rather than primary at that site;
the downstream handoff — the classification informs cancer-specific staging, diagnostic summaries, registry abstraction, treatment planning, and code selection under the applicable rules.

One compact representation is:

\[ \operatorname{SMN}(L,S,P) \iff \operatorname{Malignant}(L) \land \operatorname{LocatedAt}(L,S) \land \operatorname{AttributedToOrigin}(L,P) \land S \ne P. \]

Here \(L\) is the lesion, \(S\) its current site, and \(P\) the primary origin. AttributedToOrigin is a clinical-evidential judgment, not a conclusion licensed by the formula. When the primary is unknown, \(P\) can remain existentially unspecified: the claim is that some primary distinct from \(S\) generated the lesion, not that its location has already been discovered.

Recognition test. A case qualifies when malignant involvement at one site is documented as derived from cancer originating elsewhere and the description preserves both the involved site and the cancer's primary identity. It fails when there is only a suspected lesion, a second independent primary, local persistence without a secondary site, direct extension handled solely as local invasion, or a code chosen without supporting clinical documentation.

What It Is Not¶

Not metastasis as an entire process. Metastasis includes escape from the primary tumor, transport through lymph or blood or body cavities, lodging, and colonization. A secondary malignant neoplasm is the malignant lesion or site classification produced by that process.^[6]
Not a primary malignant neoplasm of the involved organ. A lung lesion made of metastatic breast-cancer cells is not primary lung cancer; origin, not current address alone, controls the lineage name.^[2]
Not a second primary cancer. A new independent cancer in a person with previous cancer has a new origin. Earlier radiotherapy or chemotherapy can raise that risk, but treatment causation does not turn the new primary into a metastatic secondary lesion.^[3]^[4]
Not recurrence as a purely temporal category. Recurrence means cancer returns after a period in which it was undetectable. It may be local, regional, or distant. A distant recurrence can also instantiate secondary malignant neoplasm, but the terms answer different questions: recurrence asks when relative to remission; secondary site asks where relative to origin.^[8]
Not direct local extension by default. Contiguous invasion beyond an organ boundary and discontinuous metastatic involvement can be treated differently by disease-specific staging and coding systems. Adjacency alone is not an origin-attribution rule.
Not cancer of unknown primary as a contradiction. A metastatic lesion may clearly be secondary even when the exact primary site is not known. NCI defines cancer of unknown primary as metastatic tumors for which the starting site cannot be identified.^[9]
Not an ICD code. C77–C79 encode families of secondary sites. The abstraction is the documented medical relation those codes represent. The appropriate code and sequencing depend on the current classification, encounter, jurisdiction, and documentation.^[5]^[7]
Not permission to diagnose from a scan or symptom. Primary-versus-secondary attribution requires professional evaluation and may integrate imaging, pathology, clinical history, and disease-specific evidence.

Scope of Application¶

The home domain is oncology, especially metastatic-disease documentation. Anatomic pathology contributes morphology and immunophenotypic or molecular evidence about likely origin. Radiology identifies distributions that may support or challenge a metastatic interpretation. Clinical oncology combines those findings with the known primary, disease behavior, and temporal history. Cancer staging records the extent appropriate to the particular cancer. Registries preserve primary and secondary-site information for surveillance, while clinical coding translates documented facts into the current code set.

The abstraction applies to regional or distant secondary involvement when authoritative clinical and classification practices describe it as secondary. ICD-10 separates secondary lymph-node disease (C77), secondary respiratory and digestive organ disease (C78), and secondary disease of other or unspecified sites (C79). These groupings show stable recurrence across many primaries and organs, not dependence on a single tumor type.^[5] They also show why the concept is not just “stage IV”: lymph-node involvement can be secondary without every cancer system assigning the same stage, and stage is governed by cancer-specific rules.

The scope includes cases in which the primary tumor is no longer present. CMS guidance states that, when a prior primary site has been eradicated and there is no current primary malignancy there, documented extension, invasion, or metastasis to another site is represented as secondary malignant neoplasm at that site, with the former primary represented through history as appropriate.^[7] The lesion's status therefore does not depend on simultaneous visibility of the primary.

This entry is informational and conceptual. It does not supply a diagnostic algorithm, treatment recommendation, prognosis, or coding instruction for an individual patient. Those actions require current disease-specific guidance and qualified professionals.

Clarity¶

The fastest diagnostic is to ask two questions separately:

What malignant lineage is this? That identifies the cancer by its origin or best-supported primary identity.
Where is it now documented? That identifies the involved site.

If both answers name the same origin site and no spread is established, the lesion is primary at that site. If the involved site differs and the lesion is attributed to the original cancer, it is secondary at the involved site. If a new lesion has an independent origin, it is another primary. If the same cancer returns after an interval, it is recurrent; the recurrence may additionally be secondary when it appears at another site.

This separation blocks a common naming error. “Cancer in the liver” is location-only language. It does not determine whether the patient has primary liver cancer or metastatic colon, breast, lung, pancreatic, or another cancer involving the liver. NCI's example makes the same point with breast cancer in the lung: the tissue's lineage remains breast cancer.^[1] A complete statement such as “secondary malignant neoplasm of liver from colorectal primary” carries both coordinates.

Evidence can be incomplete without making the concept incoherent. In cancer of unknown primary, clinicians may know that a lesion is metastatic from somewhere else based on morphology and distribution yet remain unable to locate the primary. The valid statement is then “secondary malignancy at site \(S\), primary unknown,” not “primary cancer of \(S\)” and not a fabricated origin.^[9]

Manages Complexity¶

Cancer descriptions must coordinate location, lineage, time, and certainty. A one-site label cannot carry all four. Secondary malignant neoplasm manages this complexity by preserving a relational record: current site \(S\) is linked back to primary origin \(P\), while the cancer's identity travels with that link. This prevents anatomical location from overwriting biological provenance.

The distinction supports modular work. Pathology can assess whether morphology fits the known primary. Radiology can enumerate involved sites. Oncology can interpret extent and select disease-specific therapy. A registry can record origin and spread without inventing a new primary for every involved organ. Coding can represent why an encounter is focused on a metastatic site. Each practice uses the same relation while contributing a different evidential or operational layer.

The relation also localizes uncertainty. If a liver lesion is confirmed malignant but origin is unresolved, the uncertainty belongs to AttributedToOrigin, not to malignancy or location. If origin is known but a small bone finding is indeterminate, uncertainty belongs to whether secondary involvement is established at the bone. This is more informative than treating the whole case as simply “cancer present.”

Abstract Reasoning¶

If a lesion at site \(S\) matches and is attributed to a known primary at \(P\), changing its current location does not change its cancer lineage; the name follows \(P\), while the secondary-site qualifier records \(S\).
If two malignant lesions occupy noncontiguous sites, multiplicity alone cannot determine that one is secondary. They may be metastatic or separate primaries; documentation and clinicopathologic evidence must resolve the relation.^[7]
If treatment occurred before a new malignancy, chronology and causal risk do not establish metastatic lineage. A treatment-related new cancer is still a second primary when it arose independently.^[3]
If a primary tumor has been removed but a proven metastatic lesion remains, the secondary-site relation remains valid because lineage does not require the primary mass to remain physically present.
If the primary site is unknown but the lesion's morphology cannot plausibly be primary at the observed site, the secondary classification can remain justified while the origin variable stays unresolved under applicable rules.^[5]
If cancer returns locally after remission without involvement elsewhere, recurrence is present but secondary-site classification need not be.
If cancer returns in a distant organ, both descriptions may be true: distant recurrence supplies the temporal relation and secondary malignant neoplasm supplies the origin–site relation.^[8]
If an ICD code is copied without documentation that the site is secondary, the code cannot supply the missing medical premise. Classification follows supported documentation, not the reverse.
If a secondary site is the focus of an encounter, that site's operational priority can change without making it the primary origin. CMS sequencing guidance explicitly allows the metastatic site to be first-listed when treatment is directed there.^[7]
If a later test identifies a previously unknown primary, the model updates \(P\) while preserving the already observed secondary site \(S\); the relation becomes more specific rather than changing kind.

Knowledge Transfer¶

Exact transfer occurs across tumor types and oncology practices. The same role structure applies to breast cancer metastatic to lung, colorectal cancer metastatic to liver, prostate cancer metastatic to bone, a secondary lymph-node deposit, or a metastatic lesion whose primary remains unknown. The organs, evidence, staging implications, and therapies change, but the origin–secondary-site distinction remains recognizable.

The entry also supports translation among documentation systems. Narrative oncology notes may name the primary and several involved sites. Pathology may phrase a specimen as “consistent with metastasis from” a particular primary. Registries preserve the site of origin separately from sites of involvement. ICD classifications group secondary sites into C77–C79. Translation succeeds when every representation preserves both the source identity and involved site; it fails when a code or location label silently substitutes one for the other.

Outside oncology, only the broader skeleton transfers: classify a present entity partly by its origin rather than by its present location. That skeleton belongs to general abstractions such as Classification and is insufficient to make a nonmedical case a secondary malignant neoplasm. Malignant behavior, cancer-cell lineage, primary-site evidence, anatomic spread, and oncology documentation are constitutive rather than decorative.

Examples¶

Breast cancer involving lung. A patient has a documented primary breast carcinoma and a lung lesion established to derive from it. The primary site is breast; the involved secondary site is lung; the lesion retains breast-cancer identity. NCI uses this example to show why the result is metastatic breast cancer rather than lung cancer.^[1]^[2]

Colorectal cancer involving liver. A liver mass attributed to a colorectal primary is a secondary malignant neoplasm of liver from colorectal cancer. “Liver cancer” without the origin qualifier would obscure the lineage and could be mistaken for a primary hepatic malignancy. This is a canonical two-coordinate case even if the liver lesion is the immediate treatment target.

Secondary disease after eradication of the primary site. Suppose the original primary has been removed and no active malignancy remains at that site, but a proven metastatic bone lesion persists. The origin remains historically specified, while bone is the active secondary site. Current CMS guidance explicitly separates a history code for the former primary site from documented secondary malignancy elsewhere.^[7]

Unknown primary with secondary lymph-node disease. Malignant tissue in a lymph node may be established as secondary although the precise primary has not yet been found. WHO guidance treats lymph-node malignancy described as secondary within C77 and illustrates that a secondary-site judgment need not always supply the origin's exact address.^[5]

Non-example: new leukemia after prior cancer therapy. Chemotherapy or radiation can increase the risk of a later independent primary cancer. That history may support a therapy-related etiology, but it does not make the new malignancy a metastatic secondary tumor from the earlier cancer. NCI categorizes the new independent cancer as a second primary.^[3]^[4]

Non-example: indeterminate pulmonary nodule. A nodule in a person with prior cancer is not automatically a secondary malignant neoplasm. It may be benign, a new lung primary, or metastatic disease. The classification requires supported attribution rather than a risk factor and an image alone.

Structural Tensions¶

Current site versus origin identity. Symptoms and local procedures concern the involved organ, while cancer naming and systemic treatment often follow the primary. The diagnostic is whether both coordinates remain explicit.
Process versus result. Metastasis explains how spread occurs; secondary malignant neoplasm records what malignant involvement now exists. The diagnostic is whether the statement describes a biological sequence or a classified lesion/site.
Specificity versus evidential restraint. Naming an exact primary improves interpretation, but overclaiming origin converts uncertainty into error. The diagnostic is whether the asserted origin is supported at the specificity stated.
Recurrence time versus secondary-site space. A distant recurrence can satisfy both abstractions, while a local recurrence may satisfy only the temporal one. The diagnostic is to ask whether the claim concerns return after remission, location away from origin, or both.
Classification interoperability versus rule dependence. Clinical, registry, staging, and coding systems share the primary/secondary distinction but differ in granularity and operational rules. The diagnostic is whether a local implementation detail is being mistaken for the general identity.
Site salience versus lineage continuity. A large or symptomatic secondary lesion can dominate care, yet prominence does not make it the primary. The diagnostic is origin, not treatment priority or lesion size.
Semantic drift around “secondary.” In ordinary speech, secondary cancer is sometimes misheard as “a second cancer” or “cancer caused by treatment.” The diagnostic is whether secondary modifies anatomical relationship to a primary or chronological order of independent primaries.

Structural–Framed Character¶

Mixed; aggregate 0.46. The abstraction has a stable structure: one malignant lineage, a primary origin, a distinct involved site, an evidence-governed origin attribution, and a rule that preserves lineage while classifying the second site. The structure can be recognized across tumor types, organs, institutions, and classification systems.

The framing remains strongly domain-bound. “Malignant,” “primary,” “metastatic,” anatomical site, histology, cancer staging, and evidentiary sufficiency derive their meaning from oncology and pathology. Institutional code sets influence operational expression, and disease-specific conventions constrain borderline cases. The concept is therefore autonomous and reusable within oncology but does not satisfy the substrate-independence bar for a prime.

Structural Core vs. Domain Accent¶

The portable core is origin-bearing identity represented separately from current location. Classification preserves the source relation rather than sorting solely by present appearance or address. Propagation helps explain the causal path by which a source produces a remote manifestation.

The domain accent supplies everything that makes the abstraction medically determinate: malignant cells; primary tumor and secondary anatomical site; metastatic routes; pathology and imaging evidence; cancer-specific staging; and clinical documentation. Remove those commitments and one obtains a general provenance-aware classification, not a secondary malignant neoplasm. Conversely, retaining the word secondary without origin attribution produces only a chronological or administrative label.

Classification is the minimal prospective parent. The entry supplies an explicit oncology rule for sorting malignant involvement into primary versus secondary categories while retaining the variables that downstream practices need. This is not mere labeling: the rule uses origin and site evidence, rejects unsupported multiplicity, and changes how the lesion is represented.

Propagation is closely related but is not proposed as a parent. Metastasis is an oncological instance of spreading from a source through bodily routes; the secondary lesion is a result and classified state of that propagation, not the whole propagation process. Provenance is only analogically adjacent because its live definition requires a documented custody history; tumor lineage does not literally involve custody transfers. Signature-Borne Provenance can illuminate how conserved morphology or molecular markers support origin inference, but no such signature is required in every accepted clinical attribution.

Relationships to Other Abstractions¶

Current abstraction Secondary Malignant Neoplasm Domain-specific

Parents (1) — more general patterns this builds on

Secondary Malignant Neoplasm is a kind of Classification Prime

Classification is the minimal prospective parent.

Hierarchy path (1) — routes to 1 parentless root

Secondary Malignant Neoplasm → Classification

Neighborhood in Abstraction Space¶

Secondary Malignant Neoplasm sits in a sparse region of the domain-specific corpus (100^th percentile for distinctiveness): few abstractions share its structure, so a faithful description tends to retrieve it precisely.

Family — Unclustered & Miscellaneous (1565 abstractions)

Nearest neighbors

Crown Group — 0.74
Phylogenesis — 0.73
Warburg Hypothesis — 0.71
Push of the past — 0.69
Death by Misadventure — 0.69

Computed from structural-signature embeddings · 2026-09-08

Not to Be Confused With¶

Secondary Treatment is the frozen semantic rematch's highest-scoring catalog neighbor, but it is a false lexical collision. That node concerns the biological stage of wastewater treatment following primary solids removal. Shared use of “secondary” does not create a structural relation.

Classification covers the general sorting operation but not the oncological roles: malignant lineage, primary anatomical origin, involved site, metastatic attribution, and cancer-specific downstream consequences. The candidate is therefore a specialized instantiation rather than exact coverage.

Propagation covers spreading through a medium or network. It does not represent the resulting lesion as cancer of origin \(P\) situated at secondary site \(S\), nor does it distinguish a metastatic lesion from a second primary or temporal recurrence.

The term must also be kept distinct from metastatic cancer as the broader disease state, metastasis as the spreading process, second primary cancer as an independent new origin, recurrent cancer as return after an interval, primary malignant neoplasm as cancer at its origin, and therapy-related malignancy as a causal category for a new cancer. These terms overlap in real cases but are not unrestricted synonyms.

References¶

[1] National Cancer Institute. “Definition of secondary cancer.” NCI Dictionary of Cancer Terms. Defines secondary cancer as cancer spread from its starting place and identifies “secondary tumor” as an alternate term. registry ↩a ↩b ↩c

[2] National Cancer Institute. “Metastatic Cancer: When Cancer Spreads.” Explains metastatic steps, primary-lineage naming, common sites, and cancer of unknown primary. registry ↩a ↩b ↩c

[3] National Cancer Institute. “Definition of second primary cancer.” NCI Dictionary of Cancer Terms. Distinguishes an independent later primary and notes that chemotherapy or radiation can increase its risk. registry ↩a ↩b ↩c ↩d

[4] National Cancer Institute. “Late Effects of Cancer Treatment.” Distinguishes a new second primary cancer from metastatic cancer. registry ↩a ↩b ↩c

[5] World Health Organization. International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, Volume 2: Instruction Manual, 2016, especially §§4.3.5B–C. Describes C77–C79 secondary-site classification and primary-versus-secondary rules. registry ↩a ↩b ↩c ↩d ↩e

[6] National Cancer Institute. “Definition of metastasis.” NCI Dictionary of Cancer Terms. Defines the spread process and the preservation of cancer type between primary and metastatic tumors. registry ↩a ↩b

[7] Centers for Medicare & Medicaid Services and National Center for Health Statistics. ICD-10-CM Official Guidelines for Coding and Reporting, FY 2026, Chapter 2 guidance. Distinguishes active primary, secondary sites, history of prior primary, and encounter-based sequencing. registry ↩a ↩b ↩c ↩d ↩e ↩f

[8] National Cancer Institute. “Recurrent Cancer: When Cancer Comes Back.” Defines recurrence and distinguishes local, regional, and distant recurrence from a new primary. registry ↩a ↩b

[9] National Cancer Institute. “Carcinoma of Unknown Primary.” Defines the case in which metastatic tumors are present but the starting site cannot be identified. registry ↩a ↩b